作者
Nazanin Mirzaei, Bibiana C Mota, Amy M Birch, Nicola Davis, Carmen Romero‐Molina, Loukia Katsouri, Emily OC Palmer, Arantxa Golbano, Laura J Riggall, Istvan Nagy, Robin Tyacke, David J Nutt, Magdalena Sastre
发表日期
2021/2
期刊
British Journal of Pharmacology
卷号
178
期号
3
页码范围
654-671
简介
Background and Purpose
Activation of type 2 imidazoline receptors has been shown to exhibit neuroprotective properties including anti‐apoptotic and anti‐inflammatory effects, suggesting a potential therapeutic value in Alzheimer's disease (AD). Here, we explored the effects of the imidazoline‐2 ligand BU224 in a model of amyloidosis.
Experimental Approach
Six‐month‐old female transgenic 5XFAD and wild‐type (WT) mice were treated intraperitoneally with 5‐mg·kg−1 BU224 or vehicle twice a day for 10 days. Behavioural tests were performed for cognitive functions and neuropathological changes were investigated by immunohistochemistry, Western blot, elisa and qPCR. Effects of BU224 on amyloid precursor protein (APP) processing, spine density and calcium imaging were analysed in brain organotypic cultures and N2a cells.
Key Results
BU224 treatment attenuated spatial and perirhinal cortex …
学术搜索中的文章
N Mirzaei, BC Mota, AM Birch, N Davis… - British Journal of Pharmacology, 2021